Business Context and Reporting Period
This Form 8-K is a current report filed by NewAmsterdam Pharma Company N.V. on July 11, 2025. The filing discloses an executive compensation arrangement update rather than periodic financial results.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on a specific employment agreement and does not contain financial statements or performance metrics.
Material Changes
On July 11, 2025, the Company entered into an amended and restated Employment Agreement with Dr. John Kastelein, Chief Scientific Officer and Director. The agreement is effective as of July 1, 2025, superseding the prior agreement dated November 18, 2022.
Guidance, Outlook, and Management Commentary
The filing details specific severance and equity acceleration provisions for Dr. Kastelein:
- Termination without cause: Entitles the executive to 12 months of base salary, any earned bonus, and a prorated bonus for the calendar year of termination.
- Change in Control: If termination without cause occurs within three months prior to a change in control, or without cause/for good reason within 12 months following a change in control, the above severance applies.
- Equity Acceleration: All time-based stock options and equity awards will accelerate to become fully exercisable or nonforfeitable upon termination under these conditions. The exercise period for certain vested options will also be extended.
The filing contains no forward-looking guidance, risk factors, or discussion of unusual items beyond the terms of this specific agreement.
Investor Verification Checklist
- Verify the total potential cash and equity payout liability associated with Dr. Kastelein's new agreement terms.
- Review the definition of "good reason" and "change in control" within the full text of the agreement (Exhibit 104).
- Confirm the impact of equity acceleration on the Company's outstanding share count and dilution.
- Check for any related proxy statements or prior filings detailing Dr. Kastelein's current base salary to calculate potential severance amounts.